The battle for control of Pliva, the Croatian generics manufacturer, on Monday descended into a war of words as Barr Pharmaceuticals continued to assert the merits of its bid. After securing a $2.2bn ...

On April 28, the US Food and Drug Administration's Center for Drug Evaluation and Research (Rockville, MD) issued a Warning Letter to Pliva Hrvatska d.o.o., a subsidiary of Pliva d.d. (Zagreb, Croatia ...

Roula Khalaf, Editor of the FT, selects her favourite stories in this weekly newsletter. Actavis on Monday appeared to concede defeat in the takeover battle for Pliva, the Croatian drugs manufacturer.

Pliva’s supervisory board issued a statement this morning lending its wholehearted support to the improved $2.5 billion offer for the business tendered by Iceland-headquartered generics group Actavis.

SAN FRANCISCO (MarketWatch) -- Barr Pharmaceuticals Inc.'s $2.3 billion cash takeover offer for Pliva DD on Wednesday received the backing of the Croatian generic drugmaker's supervisory board. Based ...

Pliva has reported a 17% decline in first-quarter revenues as royalty income from sales of Pfizer’s antibiotic Zithromax fell through the floor, but said its generics business had a ‘strong’ quarter.

Pliva?s new Oral Solid Forms Facility will increase Pliva's production capacities for tablets and capsules. Pliva's new oral solid forms facility at its production site in Zagreb will increase Pliva's ...

Pliva, a Zagreb, Croatia-based drug firm, expects to complete its exit from the proprietary drug business with an agreement to sell an R&D unit to GlaxoSmithKline. GSK will pay an up-front fee of $35 ...